Prof O’Flaherty and Dr Paul Mc Cay, in an attempt to address the growing problem of antimicrobial resistance, developed a range of non-antibiotic antimicrobial technologies. These technologies are effective against all microorganisms tested, including antibiotic-resistant organisms, such as MRSA. Additionally due to the mechanism of action of these technologies, microorganisms are highly unlikely to develop a resistance to the WWH technologies – delivering safe, effective solutions for the future.
Westway Health is developing its novel antimicrobial technologies in a range of applications in the fields of human health, animal health and environmental sterilisation. Prof O'Flaherty and WWH CEO, Dr. Ruairi Friel, lead the research team in bringing the novel PanaMast product to commercialisation, under the H2020 SME Phase 2 instrument.
Overview
FAQ about Westway Health
When was Westway Health founded?
Westway Health was founded in 2012.
How much funding has Westway Health raised?
Westway Health has raised $2.94M in total across 1 funding round.
Is Westway Health still active?
Yes, Westway Health is active; its latest activity on Parsers VC dates from Aug 10, 2017.